RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Replicel Life Sciences Stock

Replicel Life Sciences Equity 2024

Replicel Life Sciences Equity

-5.92 M CAD

Ticker

RP.V

ISIN

CA76027P4006

WKN

A2APX7

In 2024, Replicel Life Sciences's equity was -5.92 M CAD, a -13.55% increase from the -6.84 M CAD equity in the previous year.

Replicel Life Sciences Aktienanalyse

What does Replicel Life Sciences do?

Replicel Life Sciences Inc was founded in Canada in 2010 with the goal of developing cutting-edge technologies for the regeneration of body tissues. The company operates in the biotechnology, medical, and pharmaceutical fields and works closely with leading scientists and research groups. The business model of Replicel is based on the research and development of regenerative medicine, which builds on stem cell research and tissue engineering technologies. The aim is to develop new treatment options for diseases and injuries in which the body is unable to heal itself. The company has several divisions, including Replicel Cell Therapy, Replicel Skin rejuvenation, Replicel tendon regeneration, and RepliCel Hair regeneration. Each of these business areas focuses on researching specific technologies for regenerating cells and tissues in different parts of the body. Replicel Cell Therapy is developing therapies for the treatment of diseases such as arthritis, tendinitis, and joint pain. These therapies are based on stem cell research and the body's ability to regenerate damaged cells and restore healthy tissue. Replicel Skin rejuvenation focuses on the development of therapies for skin rejuvenation. The technology is based on the use of stem cells to repair damaged skin cells and promote the growth of new, healthy cells. This can improve the elasticity and firmness of the skin and help reduce wrinkles and other signs of aging. Replicel tendon regeneration is developing therapies for the treatment of tendon injuries. These injuries are often difficult to treat and can lead to long-term damage. Replicel uses its stem cell technology to repair damaged tendon cells and restore healthy, functional tissue. RepliCel Hair regeneration is developing therapies for the treatment of hair loss. The technology is based on the use of stem cells to repair damaged hair follicles and promote new hair growth. The therapy offers an alternative to traditional hair transplants and can be used in both men and women. Replicel has several products in development, including RCH-01 and RCS-01. RCH-01 is a therapy for the treatment of hair loss in men and women. The therapy is based on the use of stem cells to repair damaged hair follicles and promote new hair growth. RCS-01 is a therapy for skin rejuvenation and wrinkles. The therapy is based on the use of stem cells to promote the production of collagen and elastin in the skin. Over the years, Replicel has entered into several important partnerships and funding agreements. In 2013, the company signed an agreement with Shiseido, a leading company in the cosmetics industry. Shiseido participated in the development of RCH-01 and RCS-01 and funded the clinical trials. In 2016, Replicel received $5.5 million in funding from the Canadian government to advance the development of its stem cell technologies. Overall, Replicel Life Sciences Inc is a leading company in the field of regenerative medicine. Through its collaboration with leading scientists and researchers, the company has developed innovative technologies that can be used to treat diseases and injuries. With products like RCH-01 and RCS-01, Replicel has the potential to improve the lives of millions of people worldwide. Replicel Life Sciences ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing Replicel Life Sciences's Equity

Replicel Life Sciences's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Replicel Life Sciences's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Replicel Life Sciences's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Replicel Life Sciences's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Replicel Life Sciences’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Replicel Life Sciences stock

What is the equity of Replicel Life Sciences this year?

Replicel Life Sciences has equity of -5.92 M CAD this year.

What was the equity of Replicel Life Sciences compared to the previous year?

The equity of Replicel Life Sciences has increased/decreased by -13.55% decreased compared to the previous year.

What impact does a high equity have on investors of Replicel Life Sciences?

A high equity is advantageous for investors of Replicel Life Sciences as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of Replicel Life Sciences?

A low equity can be a risk for investors of Replicel Life Sciences, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of Replicel Life Sciences affect the company?

An increase in equity of Replicel Life Sciences can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of Replicel Life Sciences affect the company?

A reduction in equity of Replicel Life Sciences can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of Replicel Life Sciences?

Some factors that can affect the equity of Replicel Life Sciences include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of Replicel Life Sciences so important for investors?

The equity of Replicel Life Sciences is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can Replicel Life Sciences take to change the equity?

To change equity, Replicel Life Sciences can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does Replicel Life Sciences pay?

Over the past 12 months, Replicel Life Sciences paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Replicel Life Sciences is expected to pay a dividend of 0 CAD.

What is the dividend yield of Replicel Life Sciences?

The current dividend yield of Replicel Life Sciences is .

When does Replicel Life Sciences pay dividends?

Replicel Life Sciences pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Replicel Life Sciences?

Replicel Life Sciences paid dividends every year for the past 0 years.

What is the dividend of Replicel Life Sciences?

For the upcoming 12 months, dividends amounting to 0 CAD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Replicel Life Sciences located?

Replicel Life Sciences is assigned to the 'Health' sector.

Wann musste ich die Aktien von Replicel Life Sciences kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Replicel Life Sciences from 11/5/2024 amounting to 0 CAD, you needed to have the stock in your portfolio before the ex-date on 11/5/2024.

When did Replicel Life Sciences pay the last dividend?

The last dividend was paid out on 11/5/2024.

What was the dividend of Replicel Life Sciences in the year 2023?

In the year 2023, Replicel Life Sciences distributed 0 CAD as dividends.

In which currency does Replicel Life Sciences pay out the dividend?

The dividends of Replicel Life Sciences are distributed in CAD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Replicel Life Sciences

Our stock analysis for Replicel Life Sciences Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Replicel Life Sciences Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.